Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Dan Med Bull ; 58(2): A4236, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21299923

ABSTRACT

INTRODUCTION: The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula has not been validated in patients with cancer. The present investigation was undertaken in order to study how well estimated glomerular filtration rate (eGFR) using the new CKD-EPI equation correlates with measured GFR (mGFR) by (51)chrome ethylene diamine tetraacetic acid ((51)Cr-EDTA) clearance in a group of patients with cancer not known as having cancer. MATERIAL AND METHODS: We investigated 185 patients with cancer who were referred for isotope measurement of GFR with (51)Cr-EDTA before initiating chemotherapy treatment. The agreement between CKD-EPI and (51)Cr-EDTA was assessed using a Bland-Altman plot. Test performance was analysed in a contingency table and bias, precision and the percentage of estimates within 30% of the mGFR (P30) were assessed. RESULTS: Bland-Altman plot analysis showed a limit of agreement in the range from -25.59 to 27.92 ml/min./1.73 m(2). This formula was therefore not interchangeable with (51)Cr-EDTA, as the above differences are of clinical importance. Bias was low: 1.16 ml/min./1.73 m(2); P30 was high: 89.73%; and precision was 13.37 ml/min./1.73 m(2). As a screening test, the CKD-EPI had a high specificity of 98% (95% confidence interval (CI): 96 to 100%) and a high negative predictive value 97% (95% CI: 95 to 100%). The accuracy of the validation test was 96% (95% CI: 93 to 99%). CONCLUSION: The CKD-EPI may be used as a screening tool for CKD in the general population, but cannot replace isotope tests when a high GFR measurement accuracy is needed.


Subject(s)
Kidney Failure, Chronic/etiology , Kidney/pathology , Neoplasms/complications , Chelating Agents/administration & dosage , Chelating Agents/metabolism , Confidence Intervals , Creatinine/metabolism , Edetic Acid/administration & dosage , Edetic Acid/metabolism , Female , Glomerular Filtration Rate , Health Status Indicators , Humans , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/epidemiology , Kidney Failure, Chronic/pathology , Male , Middle Aged , Retrospective Studies , Sensitivity and Specificity
2.
Article in English | MEDLINE | ID: mdl-16428210

ABSTRACT

Status of the regional lymph nodes is a strong prognostic factor in patients with cutaneous malignant melanoma (CMM) and can be assessed by sentinel lymph node biopsy (SLNB). We present our technique of preoperative lymphatic mapping and intraoperative vital dye and handheld gamma probe. Our results and three years follow-up of its routine use in 198 patients with verified primary CMM are presented. Median follow-up time was 24 months (range 1-47). Metastatic regional lymph node disease was found by SLNB in 61 patients (31%) and additional metastatic nodes were found by formal node dissection in 30% of these cases. Complications were relatively mild but included one case of lymphoedema in a node negative patient. By follow-up, 13% had developed a recurrence including 26% of node positive patients and 8% of node negative patients. Mortality was also substantially higher in node positive cases with 18% dying in the follow-up period and 3% in the node negative group. The SLNB procedure was associated with a false negative rate of 8%. Using the presented technique, we found that SLNB was a useful procedure for staging patients with CMM and for selecting patients for more extensive metastatic screening and inclusion in trials of adjuvant treatments.


Subject(s)
Melanoma/pathology , Sentinel Lymph Node Biopsy , Skin Neoplasms/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Lymph Node Excision , Lymph Nodes/diagnostic imaging , Lymphatic Metastasis , Male , Melanoma/diagnostic imaging , Melanoma/mortality , Middle Aged , Neoplasm Recurrence, Local , Neoplasm Staging , Radionuclide Imaging , Radiopharmaceuticals , Skin Neoplasms/diagnostic imaging , Skin Neoplasms/mortality , Survival Analysis , Technetium Tc 99m Aggregated Albumin
SELECTION OF CITATIONS
SEARCH DETAIL
...